NeoGenomics (NEO)
(Real Time Quote from BATS)
$14.68 USD
-0.23 (-1.54%)
Updated May 21, 2024 02:34 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
NeoGenomics, Inc. [NEO]
Reports for Purchase
Showing records 41 - 60 ( 132 total )
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
NeoGenomics reported solid financial results for their Q3/2015
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Nirvana as NEO finally Transcends The CMS
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Transformational Acquisition, Target to $10
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Preview - Upcoming CMS Update a Bigger Driver than 3Q Performance
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Premier Agreement Eliminates the Covance Overhang
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Q2/15 results strong; Rates could rebound
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Impact of Proposed Reimbursement Changes, Target to $7.50
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Christmas in July as CMS Comes to the Party
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Preview - Focus on Volume Growth and Impending Reimbursement
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.